Market Closed -
Nyse
04:00:01 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
70.47
USD
|
+0.47%
|
|
+1.15%
|
+15.11%
|
Fiscal Period: März |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,549
|
1,844
|
2,198
|
2,658
|
3,112
|
3,499
|
-
|
-
|
Enterprise Value (EV)
1 |
1,549
|
1,844
|
2,198
|
2,658
|
3,112
|
4,569
|
4,325
|
4,078
|
P/E ratio
|
-43.3
x
|
13.2
x
|
13.6
x
|
13.1
x
|
-38
x
|
16.3
x
|
15.2
x
|
14.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.59
x
|
1.91
x
|
2.33
x
|
2.45
x
|
2.76
x
|
3.08
x
|
3.01
x
|
2.94
x
|
EV / Revenue
|
1.59
x
|
1.91
x
|
2.33
x
|
2.45
x
|
2.76
x
|
4.02
x
|
3.72
x
|
3.43
x
|
EV / EBITDA
|
4.67
x
|
5.62
x
|
6.68
x
|
7.23
x
|
8.23
x
|
11.9
x
|
11
x
|
10.1
x
|
EV / FCF
|
8.66
x
|
9.1
x
|
10.3
x
|
10.6
x
|
14
x
|
17
x
|
15.9
x
|
14.3
x
|
FCF Yield
|
11.5%
|
11%
|
9.71%
|
9.42%
|
7.13%
|
5.87%
|
6.3%
|
7.02%
|
Price to Book
|
1.41
x
|
1.59
x
|
1.62
x
|
1.69
x
|
2.15
x
|
2.16
x
|
1.88
x
|
-
|
Nbr of stocks (in thousands)
|
51,798
|
50,266
|
49,865
|
50,199
|
49,688
|
49,649
|
-
|
-
|
Reference price
2 |
29.91
|
36.68
|
44.08
|
52.94
|
62.63
|
70.47
|
70.47
|
70.47
|
Announcement Date
|
5/9/19
|
5/7/20
|
5/6/21
|
5/5/22
|
5/4/23
|
-
|
-
|
-
|
Fiscal Period: März |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
975.8
|
963
|
943.4
|
1,087
|
1,128
|
1,136
|
1,162
|
1,190
|
EBITDA
1 |
331.4
|
328.1
|
328.9
|
367.7
|
378.1
|
383.2
|
393.6
|
404
|
EBIT
1 |
299.6
|
299.1
|
298.8
|
326.7
|
347.8
|
350.9
|
360.5
|
369.4
|
Operating Margin
|
30.71%
|
31.06%
|
31.67%
|
30.06%
|
30.84%
|
30.9%
|
31.03%
|
31.04%
|
Earnings before Tax (EBT)
1 |
-38.06
|
191.2
|
204.1
|
262.5
|
-93.92
|
283.5
|
304
|
315.7
|
Net income
1 |
-35.8
|
142.3
|
164.7
|
205.4
|
-82.31
|
216.7
|
230.8
|
239.1
|
Net margin
|
-3.67%
|
14.77%
|
17.46%
|
18.9%
|
-7.3%
|
19.08%
|
19.87%
|
20.09%
|
EPS
2 |
-0.6900
|
2.780
|
3.250
|
4.040
|
-1.650
|
4.331
|
4.627
|
4.855
|
Free Cash Flow
1 |
178.8
|
202.6
|
213.4
|
250.3
|
221.9
|
268.1
|
272.4
|
286.1
|
FCF margin
|
18.32%
|
21.03%
|
22.62%
|
23.03%
|
19.68%
|
23.61%
|
23.45%
|
24.03%
|
FCF Conversion (EBITDA)
|
53.95%
|
61.74%
|
64.87%
|
68.08%
|
58.7%
|
69.97%
|
69.2%
|
70.82%
|
FCF Conversion (Net income)
|
-
|
142.37%
|
129.56%
|
121.86%
|
-
|
123.7%
|
118.01%
|
119.63%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/9/19
|
5/7/20
|
5/6/21
|
5/5/22
|
5/4/23
|
-
|
-
|
-
|
Fiscal Period: March |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
276.2
|
274.5
|
266.9
|
277.1
|
289.3
|
275.5
|
285.9
|
279.3
|
286.3
|
282.7
|
287.4
|
285.5
|
293.1
|
289.4
|
294.7
|
EBITDA
1 |
92.72
|
90.47
|
85.42
|
94.57
|
91.82
|
94.16
|
97.53
|
93.98
|
95.66
|
93.8
|
98.55
|
97.19
|
98.81
|
97.38
|
102.1
|
EBIT
1 |
84.76
|
82.42
|
76.94
|
86.19
|
83.57
|
86.03
|
89.22
|
85.19
|
88.25
|
86.83
|
90.68
|
88.17
|
90.28
|
89.58
|
93.37
|
Operating Margin
|
30.68%
|
30.03%
|
28.82%
|
31.11%
|
28.89%
|
31.23%
|
31.21%
|
30.5%
|
30.82%
|
30.71%
|
31.56%
|
30.88%
|
30.8%
|
30.96%
|
31.69%
|
Earnings before Tax (EBT)
1 |
59.63
|
65.49
|
60.96
|
70.9
|
66.59
|
68.12
|
-299.5
|
68.71
|
70.42
|
69.58
|
74.75
|
73.46
|
75.82
|
76
|
80.35
|
Net income
1 |
45.32
|
50.22
|
52.09
|
55.27
|
51.02
|
51.95
|
-240.6
|
53.28
|
53.56
|
53.05
|
56.87
|
55.91
|
57.7
|
57.81
|
61.16
|
Net margin
|
16.41%
|
18.3%
|
19.51%
|
19.95%
|
17.64%
|
18.86%
|
-84.15%
|
19.07%
|
18.71%
|
18.76%
|
19.79%
|
19.58%
|
19.69%
|
19.98%
|
20.76%
|
EPS
2 |
0.8900
|
0.9900
|
1.020
|
1.090
|
1.020
|
1.040
|
-4.830
|
1.060
|
1.070
|
1.060
|
1.140
|
1.116
|
1.154
|
1.156
|
1.226
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
2/3/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/2/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
1,071
|
826
|
579
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
2.794
x
|
2.099
x
|
1.434
x
|
Free Cash Flow
1 |
179
|
203
|
213
|
250
|
222
|
268
|
272
|
286
|
ROE (net income / shareholders' equity)
|
12.8%
|
13.4%
|
13%
|
14.1%
|
14%
|
13.6%
|
12.7%
|
12.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
6.3%
|
6.2%
|
5.9%
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
3,440
|
3,723
|
4,053
|
Book Value Per Share
2 |
21.20
|
23.10
|
27.20
|
31.40
|
29.10
|
32.60
|
37.40
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-
|
5.420
|
5.130
|
5.370
|
Capex
1 |
10.5
|
14.6
|
22.2
|
9.64
|
7.78
|
10.1
|
12
|
12.3
|
Capex / Sales
|
1.07%
|
1.51%
|
2.36%
|
0.89%
|
0.69%
|
0.89%
|
1.04%
|
1.03%
|
Announcement Date
|
5/9/19
|
5/7/20
|
5/6/21
|
5/5/22
|
5/4/23
|
-
|
-
|
-
|
Last Close Price
70.47
USD Average target price
74.33
USD Spread / Average Target +5.48% Consensus |
1st Jan change
|
Capi.
|
---|
| +15.11% | 3.5B | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|